REDWOOD CITY, Calif.,
Sept. 29, 2020 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced it will host a virtual Key
Opinion Leader (KOL) event on the perioperative use of DSUVIA, on
Wednesday, October 7, 2020 at
12 pm ET (9 am
PT).
The event will feature discussions and data presentations from
two separate studies on the perioperative administration of DSUVIA
with Dr. Christian Tvetenstrand,
Chairman of Surgery and Director of Trauma, United Health
Services Wilson Medical Center, New
York, and Dr. Koth
Cassavaugh, Director of Pharmacy, Auburn Community
Hospital.
Dr. Tvetenstrand will present data from a recent publication,
"Reduced Opioid Use and Reduced Time in the Postanesthesia Care
Unit Following Preoperative Administration of Sublingual Sufentanil
in an Ambulatory Surgery Setting" by Christian Tvetenstrand, MD and Michael Wolff, MD, in the Journal of Clinical
Anesthesia and Pain Management. Dr. Cassavaugh will present
data from a recently completed perioperative study of DSUVIA across
multiple types of surgical specialties at Auburn Community Hospital
that has been submitted for publication.
The live webcast of the event can be accessed by using the
following link:
https://event.webcasts.com/starthere.jsp?ei=1379798&tp_key=a00647f588
or by clicking on the webcast link on the Investors home page of
the company's website at www.acelrx.com.
About DSUVIA (sufentanil sublingual tablet), 30
mcg
DSUVIA®, known as DZUVEO® in
Europe, approved by the FDA in
November 2018, is indicated for use
in adults in certified medically supervised healthcare settings,
such as hospitals, surgical centers, and emergency departments, for
the management of acute pain severe enough to require an opioid
analgesic, and for which alternative treatments are inadequate.
DSUVIA was designed to provide rapid analgesia via a non-invasive
route and to eliminate dosing errors associated with intravenous
(IV) administration. DSUVIA is a single-strength solid dosage form
administered sublingually via a single-dose applicator (SDA) by
healthcare professionals. Sufentanil is an opioid analgesic
previously only marketed for IV and epidural anesthesia and
analgesia. The sufentanil pharmacokinetic profile
when delivered sublingually avoids the high peak plasma levels and
short duration of action observed with IV administration. The
European Commission approved DZUVEO for marketing in Europe in June
2018 and the Company is currently in discussions with
potential European marketing partners.
This release is intended for investors only. For more
information, including important safety information and black box
warning for DSUVIA, please visit www.DSUVIA.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as
DZUVEO® in Europe,
indicated for the management of acute pain severe enough to require
an opioid analgesic for adult patients in certified medically
supervised healthcare settings, and one product candidate,
Zalviso® (sufentanil sublingual tablet system, SST
system, 15 mcg), an investigational product in the U.S., is being
developed as an innovatively designed patient-controlled analgesia
(PCA) system for reduction of moderate-to-severe acute pain in
medically supervised settings. DZUVEO and Zalviso are both approved
products in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-to-host-virtual-kol-event-on-perioperative-use-of-dsuvia-301139817.html
SOURCE AcelRx Pharmaceuticals, Inc.